ORBIMED ADVISORS LLC bought TRAW

April 16, 2026 · Form 4 insider transaction

ORBIMED ADVISORS LLC bought 597,729 shares of Traws Pharma, Inc. at $1.67 per share, a transaction worth $998.2K. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 12 days after the transaction.

Direction
Acquired (buy-side)
Shares
597,729
Price
$1.67
Total value
$998.2K
Role—
SecurityCommon Stock
Transaction codeP: Open-market purchase
Transaction dateApril 16, 2026
Filing dateApril 28, 2026
Shares owned after1,203,250
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.; This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

View the original Form 4 on SEC EDGAR